Leading Healthy Eating and Activity Promotion Program

NCT ID: NCT06868524

Last Updated: 2025-12-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-10-30

Study Completion Date

2029-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of the LEAP project is to improve the health and well-being of cancer survivors and their co-survivors living in persistent poverty areas by providing healthy behavior change support. This will be done by engaging the community in adapting beneficial approaches for promoting healthy diet and regular physical activity into a program for cancer survivors and co-survivors that is appropriate for the persistent poverty context and social determinants of health.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Survivor Cancer Oncology

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Program participants

Agree to evaluate a community-based, publicly available program combining a website with optional in person group sessions.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Between the ages of 18 and 89
* English speaking
* Resident of Birmingham area or surrounding community
* History of any type of cancer or the friend or family with of a cancer survivor

Exclusion Criteria

* Serious difficulty hearing
* History of dementia or organic brain syndrome
* On primary treatment for cancer
* No other other medical, psychological, or social characteristic that would interfere with participation in evaluation
Minimum Eligible Age

18 Years

Maximum Eligible Age

89 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

University of Alabama at Birmingham

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Laura Q. Rogers, MD, MPH

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Laura Rogers, MD

Role: PRINCIPAL_INVESTIGATOR

University of Alabama at Birmingham

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Victoria Roughsedge

Role: CONTACT

205-975-2249

Sydney McGlawn

Role: CONTACT

205-934-8821

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Victoria Roughsedge

Role: primary

205-975-2249

Sydney McGlawn

Role: backup

205-934-8821

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1U54CA280770-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

IRB-300010921

Identifier Type: -

Identifier Source: org_study_id